NAFLD and HBV interplay - related mechanisms underlying liver disease progression
Open Access
- 5 December 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 965548
Abstract
Non-alcoholic fatty liver disease (NAFLD) and Hepatitis B virus infection (HBV) constitute common chronic liver diseases with worldwide distribution. NAFLD burden is expected to grow in the coming decade, especially in western countries, considering the increased incidence of diabetes and obesity. Despite the organized HBV vaccinations and use of anti-viral therapies globally, HBV infection remains endemic and challenging public health issue. As both NAFLD and HBV have been associated with the development of progressive fibrosis, cirrhosis and hepatocellular carcinoma (HCC), the co-occurrence of both diseases has gained great research and clinical interest. The causative relationship between NAFLD and HBV infection has not been elucidated so far. Dysregulated fatty acid metabolism and lipotoxicity in NAFLD disease seems to initiate activation of signaling pathways that enhance pro-inflammatory responses and disrupt hepatocyte cell homeostasis, promoting progression of NAFLD disease to NASH, fibrosis and HCC and can affect HBV replication and immune encountering of HBV virus, which may further have impact on liver disease progression. Chronic HBV infection is suggested to have an influence on metabolic changes, which could lead to NAFLD development and the HBV-induced inflammatory responses and molecular pathways may constitute an aggravating factor in hepatic steatosis development. The observed altered immune homeostasis in both HBV infection and NAFLD could be associated with progression to HCC development. Elucidation of the possible mechanisms beyond HBV chronic infection and NAFLD diseases, which could lead to advanced liver disease or increase the risk for severe complications, in the case of HBV-NAFLD co-existence is of high clinical significance in the context of designing effective therapeutic targets.Keywords
This publication has 225 references indexed in Scilit:
- Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver diseaseClinical and Experimental Immunology, 2011
- The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseasesHepatology International, 2010
- Nlrp3: An immune sensor of cellular stress and infectionThe International Journal of Biochemistry & Cell Biology, 2010
- Hepatocyte IKKβ/NF-κB Inhibits Tumor Promotion and Progression by Preventing Oxidative Stress-Driven STAT3 ActivationCancer Cell, 2010
- Mechanisms of Immune-Mediated Liver InjuryToxicological Sciences, 2010
- Interaction of Adipokines and Hepatitis B Virus on Histological Liver Injury in the ChineseAmerican Journal of Gastroenterology, 2010
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1Journal of Experimental Medicine, 2009
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory responseHepatology, 2008
- The role of CD11c+ hepatic dendritic cells in the induction of innate immune responsesClinical and Experimental Immunology, 2007
- PGC-1α controls hepatitis B virus through nutritional signalsProceedings of the National Academy of Sciences, 2006